Ralliant (NYSE:RAL) Director Buys $49,962.50 in Stock

Ralliant Corporation (NYSE:RAL) Director Kevin Bryant acquired 1,250 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was purchased at an average price of $39.97 per share, with a total value of $49,962.50. Following the acquisition, the director owned 4,653 shares of the company’s stock, valued at approximately $185,980.41. This trade represents a 36.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ralliant Price Performance

NYSE:RAL opened at $39.50 on Monday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. The business’s 50-day moving average price is $51.52 and its 200 day moving average price is $46.72. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $57.02. The firm has a market cap of $4.46 billion and a P/E ratio of 31.10.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The business had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. Ralliant’s revenue for the quarter was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, March 9th. Ralliant’s dividend payout ratio (DPR) is presently 15.75%.

Hedge Funds Weigh In On Ralliant

Several institutional investors and hedge funds have recently bought and sold shares of RAL. Danske Bank A S bought a new position in shares of Ralliant during the 4th quarter valued at $25,000. Westfuller Advisors LLC bought a new stake in Ralliant in the third quarter worth $26,000. V Square Quantitative Management LLC acquired a new position in Ralliant during the fourth quarter worth $26,000. Allworth Financial LP raised its holdings in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares in the last quarter. Finally, Palisade Asset Management LLC bought a new position in Ralliant during the third quarter valued at about $26,000.

Analyst Ratings Changes

A number of brokerages have recently commented on RAL. Morgan Stanley reiterated an “overweight” rating and set a $45.00 price objective on shares of Ralliant in a research report on Friday. Royal Bank Of Canada reduced their target price on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday. Barclays increased their price target on Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. Oppenheimer cut their price objective on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Truist Financial decreased their target price on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.30.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.